…
Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida. On October 22, 2023, Akumin Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -143.18M | -65.20M | -23.42M | 11.44M |
| Minority interest | -5.17M | -8.48M | -2.73M | -2.20M |
| Net income | -156.76M | -43.29M | -20.40M | 6.45M |
| Selling general administrative | 3.24M | 2.79M | 2.08M | 3.55M |
| Gross profit | 141.25M | 61.34M | 53.48M | 77.56M |
| Reconciled depreciation | 98.20M | 44.90M | 20.46M | 28.27M |
| Operating income | 39.43M | 13.82M | 30.94M | 45.74M |
| Interest expense | 118.01M | 62.58M | 32.78M | 28.94M |
| Tax provision | 8.41M | -30.39M | -5.75M | 2.79M |
| Net interest income | -118.01M | -62.58M | -32.78M | -28.94M |
| Total revenue | 749.63M | 421.08M | 251.28M | 247.44M |
| Total operating expenses | 710.20M | 407.26M | 220.35M | 201.70M |
| Cost of revenue | 608.38M | 359.74M | 197.80M | 169.87M |
| Total other income expense net | -64.59M | -16.45M | -21.57M | -5.36M |
| Net income from continuing ops | -151.59M | -34.81M | -17.67M | 8.65M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1765.12M | 1918.83M | 718.68M | 663.38M |
| Intangible assets | 392.10M | 414.15M | 6.75M | 9.39M |
| Other current assets | 10.35M | 7.03M | - | - |
| Total liab | 1623.82M | 1597.68M | 578.95M | 521.79M |
| Total stockholder equity | -48.20M | 105.19M | 134.21M | 138.69M |
| Other current liab | - | - | 4.69M | 7.53M |
| Capital stock | 0.90M | 228.59M | 160.97M | 152.00M |
| Retained earnings | -280.19M | -123.42M | -26.76M | -20.19M |
| Good will | 769.11M | 840.35M | 360.60M | 342.22M |
| Cash | 59.42M | 48.42M | 44.40M | 23.39M |
| Total current liabilities | 168.52M | 164.18M | 51.94M | 48.44M |
| Net debt | 1215.19M | 1163.97M | 345.59M | 317.68M |
| Short long term debt | 19.96M | 14.79M | 0.41M | 3.71M |
| Total current assets | 191.94M | 185.16M | 139.47M | 110.18M |
| Net receivables | 114.17M | 121.53M | 91.13M | 82.87M |
| Long term debt | 1254.65M | 1197.60M | 389.58M | 337.36M |
| Accounts payable | 36.62M | 34.33M | 20.40M | 21.71M |
| Non currrent assets other | 23.93M | 25.48M | - | - |
| Non current assets total | 1573.17M | 1733.66M | 579.22M | 553.20M |
| Capital lease obligations | 205.00M | 227.58M | 147.87M | 137.10M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -38.70M | -779.17M | -17.08M | -231.11M |
| Total cash from financing activities | -15.66M | 766.14M | 11.40M | 215.31M |
| Net income | -156.76M | -43.29M | -20.40M | 6.45M |
| Change in cash | 11.01M | 4.02M | 21.01M | 4.06M |
| Begin period cash flow | 48.42M | 44.40M | 23.39M | 19.33M |
| End period cash flow | 59.42M | 48.42M | 44.40M | 23.39M |
| Total cash from operating activities | 65.37M | 17.05M | 26.69M | 19.86M |
| Issuance of capital stock | 0.07M | 10.51M | 0.00M | 1.31M |
| Depreciation | 98.20M | 44.90M | 20.46M | 28.27M |
| Change to account receivables | 14.33M | 12.31M | -8.26M | -25.24M |
| Capital expenditures | 44.76M | 17.87M | 13.42M | 12.45M |
| Change in working capital | 18.12M | 20.62M | 3.59M | -27.53M |
| Stock based compensation | 3.24M | 2.79M | 2.08M | 3.55M |
| Other non cash items | 42.18M | 14.09M | 5.48M | 1.93M |
| Free cash flow | 20.61M | -0.82M | 13.27M | 7.41M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc |
-17.51 2.54% |
671.24 | 34.71 | 23.87 | 4.62 | 4.43 |
| DHR Danaher Corporation |
-0.25 0.11% |
220.36 | 29.09 | 28.01 | 5.67 | 3.20 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.77 | 22.29 | 17.95 | 1.53 | 5.98 |
| WUXAY WuXi AppTec Co. Ltd |
-0.92 3.87% |
22.85 | 23.28 | 18.73 | 1.51 | 6.24 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.